Examining Hepatitis C Virus Treatment Access
A Review of Select State Medicaid Fee-For-Service and Managed Care Programs
Last Updated on May 13, 2020 by HepFree NYC
Tags: Hepatitis C HepCX NewsRelated Articles
-
Win $150! Participate in our Logo Design Competition for Hep Awareness Events
Your logo will be printed on banners, flags, and flyers for Hepatitis Awareness events, including the Hep Free NYC Awareness Event on the steps of City Hall, May 10, 11 AM - 12 PM.
-
Webinar | Eliminating Hep B & C in the US (Hep B United)
Please join Hep B United and the National Viral Hepatitis Roundtable on Monday, April 10, 2017 at 2:00 pm EDT
-
Comment! Hep C Screening Recommendations (USPSTF)
The USPSTF gives a “B” rating for testing hepatitis C among injection drug users and others at high risk, a major improvement over previous guidelines However, the Task Force failed to match the Centers for Disease Control and Prevention’s lifesaving recommendation of testi...
-
Viekira Pak now preferred under NYS Medicaid Fee For Service (FFS)
On Feb 26th, 2015, the NYS Drug Utilization Review Board (DURB) voted unanimously to move Viekira Pak to preferred status for NYS Medicaid Fee-for-service members, and to remove restrictions based on disease prognosis and severity from the current clinical criteria for Viekira Pa...
-
USPSTF Recommends Hep B Screening in High Risk Individuals
The updated recommendation comes after growing evidence on the effectiveness of antiviral treatments, and is in line with recommendations from the CDC and the American Association for the Study of Liver Diseases. The USPSTF has a separate Grade A Recommendation on screening fo...
-
National Strategy for Elimination of Hep, Phase 2 Report Released
The report identifies new opportunities for preventing transmission and recommends steps to ensure people are tested, treated, and/or cured of hepatitis.
-
NYC Health Department Announces Strategic Plan to Combat Hepatitis C
The NYC Health Department today released the City's first-ever plan for reducing illness and death from the hepatitis C virus (HCV), a disease that now accounts for more annual deaths nationwide than HIV/AIDS
-
FDA Approves Zepatier for Treatment of Hep C
The U.S. Food and Drug Administration has approved Zepatier with or without ribavirin for the treatment of chronic Hepatitis C genotypes 1 and 4 infections in adult patients.
